J. Bosch

Mr imaging as an additional s creening Modality for the Detection of Breast cancer in Women aged 50-75 Years with extremely Dense Breasts: The

N. Karssemeijer, R. Mann, R. Pijnappel, 2015 .

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006–05)

H. Putter, E. Rutgers, J. Nortier, 2017 .

Abstract S1-04: Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

H. Putter, J. Nortier, J. Kroep, 2017 .

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

M. Lübbert, U. Germing, P. Wijermans, 2005, Annals of Hematology.

High-Grade Acute Organ Toxicity as Positive Prognostic Factor in Primary Radio(chemo)therapy for Locally Advanced, Inoperable Head and Neck Cancer

H. Christiansen, T. Overbeck, C. Hess, 2010, Strahlentherapie und Onkologie.

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Faith Davies, Edie Weller, Kenneth Anderson, 2004, Mayo Clinic proceedings.

Abstract P2-09-08: Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)

H. Putter, J. Nortier, J. Kroep, 2017 .

Phase II study of paclitaxel (taxol, gemcitabine, and cisplatin for patients with advanced ovarian cancer)

H. Pinedo, R. Verheyen, K. Hoekman, 2001 .

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

A. Jager, S. Linn, H. van Tinteren, 2014, European journal of cancer.

High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.

H. Putter, J. Nortier, E. Kranenbarg, 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.